Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 7:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Differentiated Thyroid Cancer Clear all
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Thyroid Carcinoma
Interventions
LBH589
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
3
States / cities
Green Bay, Wisconsin • Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced May 21, 2026, 7:25 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer, Stage IVA Papillary Thyroid Cancer, Stage IVB Follicular Thyroid Cancer, Stage IVB Papillary Thyroid Cancer, Stage IVC Follicular Thyroid Cancer, Stage IVC Papillary Thyroid Cancer, Thyroid Gland Medullary Carcinoma
Interventions
sunitinib malate
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced May 21, 2026, 7:25 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Thyroid
Interventions
Metformin Hydrochloride, Radioactive Iodine, Placebo
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years to 90 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced May 21, 2026, 7:25 PM EDT
Not listed Phase 2 Interventional
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
rosiglitazone maleate
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced May 21, 2026, 7:25 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Metastatic Differentiated Thyroid Cancer, Metastatic Poorly Differentiated Thyroid Cancer, Metastatic Anaplastic Thyroid Cancer, Metastatic Medullary Thyroid Cancer
Interventions
sorafenib
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced May 21, 2026, 7:25 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Tumors, Solid Malignant Tumors, Osteosarcoma, Differentiated Thyroid Cancer (DTC)
Interventions
Lenvatinib, Ifosfamide, Etoposide
Drug
Lead sponsor
Eisai Limited
Industry
Eligibility
2 Years to 25 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced May 21, 2026, 7:25 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Differentiated Thyroid Cancer
Interventions
Vandetanib (SAR390530), Placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
10
States / cities
Little Rock, Arkansas • Torrance, California • Lexington, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced May 21, 2026, 7:25 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Differentiated Thyroid Cancer, Advanced Cancer
Interventions
LENVATINIB
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced May 21, 2026, 7:25 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Thyroid Cancer, Thyroid Cancer, Medullary, Differentiated Thyroid Cancer, Papillary Thyroid Cancer, Follicular Thyroid Cancer, Poorly Differentiated Thyroid Gland Carcinoma
Interventions
Lenvatinib, Sorafenib, Cabozantinib, Vandetanib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced May 21, 2026, 7:25 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Papillary Thyroid Cancer, Follicular Thyroid Cancer, Differentiated Thyroid Cancer
Interventions
SU011248, Sutent
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced May 21, 2026, 7:25 PM EDT
Approved For Marketing No phase listed Expanded access
View directory record Official record
Conditions
Differentiated Thyroid Cancer
Interventions
Lenvatinib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Timeline
Ends 2015
U.S. locations
13
States / cities
La Jolla, California • Stanford, California • Torrance, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced May 21, 2026, 7:25 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8, Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8, Thyroid Gland Squamous Cell Carcinoma, Unresectable Thyroid Gland Carcinoma
Interventions
Lenvatinib, Pembrolizumab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced May 21, 2026, 7:25 PM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Differentiated Thyroid Gland Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Refractory Differentiated Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma, Tall Cell Variant Thyroid Gland Papillary Carcinoma, Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma, Thyroid Gland Papillary Carcinoma
Interventions
Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
33
States / cities
Duarte, California • Los Angeles, California • Newport Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced May 21, 2026, 7:25 PM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Papillary Thyroid Carcinoma
Interventions
GSK2118436
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced May 21, 2026, 7:25 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present, Metastatic Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma, Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8, Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8, Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8
Interventions
Binimetinib, Encorafenib, Nivolumab
Drug · Biological
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced May 21, 2026, 7:25 PM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Decision Aid, Usual Care
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced May 21, 2026, 7:25 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Differentiated Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma, Thyroid Gland Papillary Carcinoma
Interventions
Lenvatinib
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced May 21, 2026, 7:25 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage II Follicular Thyroid Cancer, Stage II Papillary Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer
Interventions
Bortezomib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
9
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced May 21, 2026, 7:25 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8, Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8, Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8, Thyroid Gland Anaplastic Carcinoma, Unresectable Thyroid Gland Carcinoma
Interventions
Atezolizumab, Bevacizumab, Cobimetinib, Nab-paclitaxel, Paclitaxel, Vemurafenib
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced May 21, 2026, 7:25 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Differentiated Thyroid Cancer, Pediatric Cancer, Cancer, Cancer, Thyroid
Interventions
Selpercatinib Monotherapy, 131I Therapy
Drug · Radiation
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 25 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
4
States / cities
Philadelphia, Pennsylvania • Memphis, Tennessee • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced May 21, 2026, 7:25 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Euthyroid Group
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
2
States / cities
Baltimore, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced May 21, 2026, 7:25 PM EDT
Active, not recruiting Phase 3 Interventional Results available
View directory record Official record
Conditions
Differentiated Thyroid Cancer
Interventions
Cabozantinib, Placebo
Drug
Lead sponsor
Exelixis
Industry
Eligibility
16 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
31
States / cities
Newport Beach, California • Sacramento, California • San Francisco, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced May 21, 2026, 7:25 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer, Malignant Neoplasms, Brain Neoplasms, Advanced or Metastatic Solid Tumors, HGG, LGG, Low Grade Glioma, High Grade Glioma, Differentiated Thyroid Cancer, NSCLC (Non-small Cell Lung Cancer)
Interventions
PF-07799544, PF-07799933
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
58
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Rogers, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 21, 2026, 7:25 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Thyroid Carcinoma, Thyroid Cancer, Thyroid Cancer, Follicular, Thyroid Cancer (Follicular Cell), Thyroid Cancer, Papillary, BRAF V600E Mutation Positive
Interventions
I-124 PET/CT lesion dosimetry, Vemurafenib, Copanlisib
Diagnostic Test · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced May 21, 2026, 7:25 PM EDT